CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) PRIMARY BILIARY CHOLANGITIS (PBC) THROMBOCYTOPENIA
NASH HCC
About CLDF
Board of Trustees Board of Advisors/Faculty 2020 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Annotations Abstract Library Committee Members Conference Highlights
 
HBV | Annotated Bibliography
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of annotations deemed relevant to CLDF by the Board of Trustees and its Advisors.

1.Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
 

Lok AS1, Zoulim F2, Dusheiko G3, Chan HLY4, Buti M5, Ghany MG6, Gaggar A7, Yang JC7, Wu G7, Flaherty JF7, Subramanian GM7, Locarnini S8, Marcellin P9. Hepatol Commun. 2019 Oct 10;4(1):8-20. doi: 10.1002/hep4.1436. eCollection 2020 Jan.
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.